Compare Adaptive Biotechnologies Corp (ADPT) vs Zoom Video Communications, Inc. (ZM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Zoom Video Communications, Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $25.41 (market cap $4.04B), while Zoom Video Communications, Inc. trades at $105.77 (market cap $31.10B). The key difference: Zoom Video Communications, Inc. is far larger — about 7.7× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Zoom Video Communications, Inc. nearer its low. Which is the better fit depends on your goals.
| ADPT | ZM | |
|---|---|---|
Market Cap | $4.04B | $31.10B |
Sector | Health | Technology |
52-Week High | $25.45 | $111.88 |
52-Week Low | $12.30 | $69.96 |
Enterprise Value | $4.10B | $23.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adaptive Biotechnologies (ADPT) trades at $25.24, near its 52-week high, with a bullish technical outlook. The company is executing a strategic separation into a pure-play MRD diagnostics business, showing strong revenue growth of 49% year-over-year in MRD and improving margins. Despite persistent net losses, cash flow turned positive in 2025, and recent earnings have mostly beaten expectations, indicating operational progress.
The outlook is cautiously optimistic, driven by the business separation potentially unlocking value and the MRD segment's growth. Key risks include sustained profitability challenges and high valuation multiples. Analyst consensus is bullish with a $25.50 price target, but investors should weigh the growth potential against the company's current lack of earnings.
Zoom Communications (ZM) trades at $104.70, down 2.33% today, with mixed technical signals showing bullish moving averages but overbought RSI levels. The company maintains strong profitability with 77.4% gross margins and 42% net income margin, though recent earnings show volatility with one miss in the last four quarters. Recent news highlights CEO and director stock sales totaling over $7 million in July-August 2026, while the company continues AI product development and APAC expansion.
Outlook remains cautiously optimistic with a $118.79 consensus price target representing 13% upside potential. Key opportunities include sustained profitability and AI-driven growth initiatives, while risks center on insider selling pressure and competitive threats in the video communications space. The stock faces near-term technical resistance at $107-$109 levels with support at $103-$105.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Zoom Video Communications, Inc.
Zoom Video Communications, Inc. develops a people-centric cloud service that transforms real-time collaboration experience. The Company offers unified meeting experience, a cloud service that provides a 3-in-1 meeting platform with HD video conferencing, mobility, and web meetings. Zoom Video Communications serves customers worldwide.
Read more on ZM →
